Illumina, Inc.
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ILMN.MX | 4544.T | NTRA | QGEN | A | 4694.T | |
|---|---|---|---|---|---|---|
| Market cap | 765.59B | 199.33B | 58.20B | 9.60B | 48.28B | 143.37B |
| P/E (TTM) | 52.6 | 21.6 | — | 23.6 | 33.8 | 18.3 |
| Forward P/E | — | 36.1 | -1,752.6 | 17.8 | 25.4 | 25.7 |
| Price/book | 14.6 | 1.5 | 31.8 | 2.9 | 6.6 | 1.1 |
| Dividend yield | — | 3.36% | — | 0.76% | 0.59% | 3.26% |
| 1-year change | +176.30% | −5.83% | +108.61% | −5.22% | +20.96% | +5.94% |
| Today | 0.00% | −0.78% | +2.62% | +0.74% | −1.01% | −0.26% |
The closest companies by business and industry (Diagnostics & Research). Prices may be delayed up to 20 min.
Latest news
All ILMN.MX news ›Illumina (ILMN) Receives a Buy from J.P. Morgan
J.P. Morgan analyst Casey Woodring maintained a Buy rating on Illumina yesterday and set a price target of $320.00. The company’s shares closed yesterday at $262.54. Woodring covers the Healthcare sector, focusing on stocks such as…
Illumina Establishes New Dealer Agreement to Support Financing
Illumina ( (ILMN) ) has shared an announcement. On October 13, 2026, Illumina, Inc. entered into a material definitive agreement formalized through a dealer agreement with an unnamed dealer party. The filing, signed by Chief Financial…
In Brief: Illumina, Interpace, Ocugen, Roots, Elicera, Verily
In Brief This Week: Illumina, Interpace, Ocugen, Roots, Elicera, Verily, Quantum-Si, More GenomeWeb NEW YORK â Illumina this week entered into definitive documentation to establish an unsecured commercial paper program, which will…
Illumina, Inc. Launches BioInsight Platform And Releases DRAGEN v4.6
Illumina, Inc. debuted the Illumina BioInsight Platform, the company's first unified software environment designed to help researchers turn complex genomic and multiomic data into meaningful ...
Illumina Combines Multiomics Informatics Applications in New BioInsight Platform
Genetic Engineering and Biotechnology News Ahead of the 2026 meeting of the American Society of Human Genetics (ASHG), Illumina announced the launch of the BioInsight platform, a new unified software environment that provides tools to help…
Illumina Launches BioInsight Platform For Genomic And Multiomic Research
The BioInsight business includes programs such as the Billion Cell Atlas, a data-driven initiative that links proprietary information with biopharma partnerships to support drug discovery and development. DRAGEN is Illumina's software…
Illumina Launches BioInsight Platform for Data Analysis Tools
Illumina Consolidates Data Analysis Products Into New Platform, Pricing Model GenomeWeb Illumina Consolidates Data Analysis Products Into New Platform, Pricing Model
Illumina Debuts BioInsight Platform Unifying AI, Software, and Data
Illumina on October 14, 2026 debuted the Illumina BioInsight Platform, which the company describes as its first unified software environment for turning complex genomic and multiomic data into meaningful biological evidence. The platform…
Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs
Investing News Network Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs The new platform brings together advanced analysis, purpose-built AI, and curated…
JPMorgan Adjusts Price Target on Illumina to $320 From $230
www.marketscreener.com Advanced Medical Equipment & Technology JPMorgan Adjusts Price Target on Illumina to $320 From $230 Published on 10/14/2026 at 07:05 am EDT
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketscreener.com26
-
tradingview.com7
-
theglobeandmail.com6
-
newsfilecorp.com4
-
stocktitan.net4
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 73 articles, not a forecast.